Niche CDMO adds spray drying for highly potent drugs

28 Mar 2018

The investment makes Idifarma one of only three companies in the world offering this type of contract development and manufacturing spray drying service.

IDIFARMA has announced new GMP spray drying capabilities which will make it one of the very few CDMO to offer spray drying technology for highly potent drugs up to Category 4 OEL/OEB.

Niche CDMO adds spray drying for highly potent drugs

The Spanish CDMO, which specialises in niche and highly potent products, will be one of only three companies in the world offering this type of contract development and manufacturing spray drying service with the installation of GEA Niro Mobile Minor equipment in a new dedicated area in its 4,000 sq. ft EU GMP plant.

The new equipment, which involves a significant investment for the company, will be installed and qualified in mid-2018 and will give Idifarma spray drying capacity for niche commercial products and clinical batches.

Luis Oquiñena, general manager and co-founder of Idifarma said: “We are excited to announce this new service and very proud to be at the forefront of spray drying technology. By making this investment, we will be able to provide contract manufacturing services for intermediate products, and for oral solid drugs we can continue until the finished dosage forms.

“This investment is driven by significant client demand, with the market looking for spray drying solutions as a suitable technology to improve the bioavailability of poorly soluble drugs. Idifarma now has all the ingredients to support our customers’ spray drying projects at different scales and contribute to accelerated drug development and manufacturing timelines.”

This announcement follows recent investment in both serialisation and capsule filling capabilities and strengthens Idifarma’s position as a specialised contract partner for the development and manufacturing of oral solid dosage forms, including high potency compounds and niche pharmaceuticals requiring small commercial and clinical batches.

Oquiñena added: “Our investment in new technologies reflects our continued success within the CDMO market and our intent to further grow our business with specialised capabilities. As well as new technologies we are also investing in qualified and experienced staff to deliver our services and now have 120 employees on site. As customer demand for our niche CDMO services continues to grow we fully expect both investments and staff numbers to increase steadily in the coming year.”

Read More

Related tags

Market News

Related news

iNova Pharmaceuticals announces the launch of iPitch 2020

iNova Pharmaceuticals announces the launch of iPitch 2020

3 Jul 2020

Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.

Read more 
Ajinomoto introduces fast track platform for drug product manufacturing

Ajinomoto introduces fast track platform for drug product manufacturing

30 Jun 2020

AJILITY is designed to speed novel or existing therapeutics from development to manufacturing and into the clinic.

Read more 
CPhI Worldwide to transform into Festival of Pharma digital experience

CPhI Worldwide to transform into Festival of Pharma digital experience

30 Jun 2020

The 10-day event will feature an interactive digital marketplace for sourcing products and services, enhanced matchmaking for connecting with new and existing partners, and world-renowned speakers.

Read more 
Catalent expands beauty and plant-based consumer health softgel capabilities

Catalent expands beauty and plant-based consumer health softgel capabilities

30 Jun 2020

Two company sites - one in Canada, the other in Brazil - receive new softgel encapsulation lines to service local customer demand.

Read more 
Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

Stevanato Group pledges to provide glass vials for potential COVID-19 vaccines

29 Jun 2020

The company agrees to provide CEPI with 100 million glass vials, which can store 20 doses per vial (2 billion doses in total).

Read more 
PCI Pharma Services completes biotech Center of Excellence

PCI Pharma Services completes biotech Center of Excellence

29 Jun 2020

The global outsourcing solutions provider is also set to expand its biotech capabilities in Europe.

Read more 
DuPont's seaweed-based soft capsule ingredient gains non-GMO certification

DuPont's seaweed-based soft capsule ingredient gains non-GMO certification

29 Jun 2020

SeaGel offers drug and dietary supplement manufacturers an animal-free and sustainable alternative to traditional soft capsules.

Read more 
Gilead pencils in potential buyout of Pionyr Immunotherapeutics

Gilead pencils in potential buyout of Pionyr Immunotherapeutics

23 Jun 2020

Pionyr's "promising, novel biology" could represent a major increase in Gileads's cancer pipeline.

Read more 
CordenPharma & Moderna extend lipid supply agreement for Moderna’s coronavirus vaccine

CordenPharma & Moderna extend lipid supply agreement for Moderna’s coronavirus vaccine

23 Jun 2020

The amended manufacturing agreement, which originally specified CordenPharma facilities Switzerland, now extends to the CDMOs France and US sites.

Read more 
TraceLink announces results from FDA DSCSA Pilot Program

TraceLink announces results from FDA DSCSA Pilot Program

23 Jun 2020

Key findings demonstrate the value of network solutions to secure and digitalize the pharmaceutical supply chain.

Read more